Akụkọ

NEW YORK, June 23, 2022 (GLOBE NEWSWIRE) - Reportlinker.com na-ekwupụta mwepụta nke akụkọ ahụ "Global Intravenous Therapy and Intravenous Access Market Size, Share and Industry Trends Analysis Report, Outlook na amụma nke Onye ọrụ njedebe, ngwa, ụdị, mpaghara . ọgwụ a.N'okwu a, a ga-agwọ onye ọrịa ahụ ọgwụ ngwa ngwa o kwere mee, si otú a na-enye ọgwụ ahụ n'ime intravenously. Ọgwụgwọ chemotherapy, ọgwụ nje, antifungals, ihe na-enye mgbu, ọgwụgwọ globulin na-alụso ọrịa ọgụ, na ọgwụ ọbara mgbali elu na-enye ọgwụgwọ intravenous. (IV) bụ usoro a na-ebuga ọgwụ na mmiri mmiri n'ime ahụ site na vein. A na-enye ọgwụ ndị nwere vitamin na mineral site na ntanye nke eriri afọ ma ọ bụ ntụtụ n'ime eriri afọ, na-ekwe ka ọgwụgwọ na-agafe ngwa ngwa site na ọbara. Dị ka Scope, nchịkwa IV bụ mgbe. Onye ọrịa na-eji tube a na-akpọ cannula tinye ihe ndị dị n'ime akwara ozugbo. Nke a nwere ike ịbụ mmetụta dị n'akụkụ nke ọgwụ ma ọ bụ ụkọ nri. .N'oge nchịkwa IV, a na-eji ngwá ọrụ IV dị iche iche dị ka IV catheters, infusion pumps, immobilization devices, and management kits. na-ebelata ọrịa na-adịghị ala ala karịa ọgwụgwọ ọnụ. Ọ nwere mgbapụta infusion nke na-achịkwa ọnụọgụ kemịkalụ a ga-enye ahụ ma nwee ike nyochaa ngwa ngwa. A na-atụ anya na ahịa ọgwụgwọ intravenous zuru ụwa ọnụ na ngwaọrụ ịnweta eriri afọ ga-abawanye n'oge amụma. ọrịa shuga mellitus, ịrị elu nke ihe mberede okporo ụzọ, na mmụba nke usoro ịwa ahụ ga-eme ka ụlọ ọrụ ahụ gaa n'ihu. A na-ebutekwa ụlọ ọrụ ahụ site n'ịchọwanye usoro ndị siri ike, dị ka nnyefe ọgwụ na-enweghị agịga. COVID-19 Mmetụta COVID-19 nwere. N'ime ndị ọrịa nwere nnukwu ọrịa iku ume iku ume metụtara COVID-19, a na-enye ọgwụgwọ IV (ARDS) dịka ọmụmaatụ, iji ọgwụ mgbochi globulin intravenous maka ọgwụgwọ COVID-19 ARDS dịka ọmụmaatụ. Ebipụtara adjuvant mara mma maka ọgwụgwọ ARDS siri ike nke COVID-19 na The Lancet Respiratory Medicine na Nọvemba 11, 2021 n'ihi na ọ nwere ike ịgbanwe ọtụtụ ngalaba mgbochi n'otu oge. Ya mere, na mmụba nke ọnụ ọgụgụ ndị ọrịa nwere COVID-19. -ihe metụtara ARDS, ọchịchọ nke ọgwụgwọ IV na ngwaahịa ịnweta intravenous na-abawanye. Ihe na-akpata uto ahịa na-abawanye ọrụ na ọnụ ọgụgụ ndị Geriatric Ọnụ ọgụgụ nke ọrịa dị iche iche na-adịghị ala ala na-achọ ọgwụgwọ ịnweta vaskụla abawanyela n'ime afọ iri gara aga. Ọrịa na-adịghị ala ala dị ka ọrịa cancer, akụrụ akụrụ na ọrịa obi, yana ụdị ndụ dị iche iche dị ka ọbara mgbali elu, ọrịa shuga, oke ibu na ịda mbà n'obi, chọrọ nlekọta kpụ ọkụ n'ọnụ n'oge ọnụnọ ụlọ ọgwụ. N'ime afọ ole na ole sochirinụ, ibu arọ nke ọrịa na-adịghị ala ala dị ka ọrịa obi, ọrịa cancer, ọrịa strok, na ọrịa shuga. , tinyere ọnụ ọgụgụ ndị merela agadi, ga-eme ka ọ dịkwuo mkpa maka ọgwụgwọ intravenous. Ọganihu Teknụzụ Ọganihu Na-ahụ Maka Ọdịnihu (peripheral na Central), ngwa ndị nwere ngwaọrụ nchekwa, na nfuli infusion n'ọnụ bụ otu n'ime ihe ndị na-emepụta ihe na-eme ka usoro ọgwụgwọ intravenous dịkwuo mma, dị elu (nke dị elu). IVT) omume. Dị ka nkà na ụzụ ahụike bụ ịdọ aka ná ntị dị mgbagwoju anya, na-atụgharị uche na mkparịta ụka kwa ụbọchị site n'aka ndị ọkachamara ahụike na-etinye aka na nlekọta ndị ọrịa na ngalaba nlekọta ahụike, ngalaba nlekọta ahụ enweela mgbanwe dị ukwuu n'ihi ntinye nke teknụzụ ọhụrụ, na nfuli infusion nke egbugbere ọnụ bụ Otu n'ime akụrụngwa teknụzụ iji nyere aka nweta usoro ọgwụgwọ intravenous (IVT) dị mma ma dị elu. Ahịa Mgbochi Mgbapụta mgbapụta chọrọ iwu siri ike na nchegbu banyere nsogbu. A na-ebugharị usoro ikikere maka ọrụ ọhụrụ na mmepụta nke mgbapụta na nchikota. Tụkwasị na nke ahụ, ịrị elu ngwaahịa na-echeta n'ihi mmebi nke nrụpụta ga-ebelata nnabata nke usoro ọgwụgwọ ndị a. Dịka ọmụmaatụ, Fresenius Kabi chetara Vigilant Agilia Drug Depot na Volumat MC Agilia Infusion Pump in August 2019 n'ihi infusion njikere okwu, dị ala-ebute ụzọ Keep Vein Open (KVO) na ndị ọzọ software chinchi.Ihe mgbochi na uto nke ụlọ ọrụ bụ nsogbu ndị metụtara na iji IV ụzọ na IV infusion ngwaahịa.End User Outlook Dabere. na njedebe onye ọrụ, a na-ekewa ahịa ahụ n'ime ụlọ ọgwụ, ụlọ ọrụ ịwa ahụ ambulator, na ụlọ ọgwụ. Ngalaba ụlọ ọgwụ ga-ejide oke ego ntinye ego na ọgwụgwọ intravenous (IV) na ahịa ịnweta venous na 2021. Nke a bụ n'ihi mmụba nke ọnụ ọgụgụ ahụ. nke ịwa ahụ a na-eme ma e jiri ya tụnyere ụlọ ọrụ ịwa ahụ ambulator na ụlọ ọgwụ. Tụkwasị na nke ahụ, a na-ekwu na ọganihu nke akụkụ ahụ bụ mmụba nke ọgwụgwọ intravenous na ụlọ ọgwụ, nke gụnyere ọgwụ nje ọgwụ nje, ọgwụ maka ndị na-arịa ọrịa comatose, ọgwụ ndị na-enweghị ike ịṅụ ọnụ, ntinye aka. redio, ọgwụ anticancer, hemodialysis, ikwugharị maapụ ọbara, na mmịnye ọbara .Ahịa maka ọgwụgwọ IV na ngwaọrụ ohere venous na-eto eto n'ihi ọganihu teknụzụ na itinye ego n'ụlọ ọgwụ. Ngwa ngwa Na ndabere nke ngwa, a na-ekewa ahịa ahụ n'ime nchịkwa ọgwụ. , Ngwaahịa sitere n'ọbara, ihe oriri na-edozi ahụ na ihe nchekwa, na arịa mgbasawanye.Na 2021, ngalaba Expander nke Mpịakọta ga-enweta oke ego ha nwetara na ọgwụgwọ intravenous (IV) na ahịa ịnweta venous. Mmiri mmiri n'ime mmiri nwere ike ịba uru maka ọnụ ọgụgụ dị nta nke mmiri. - ndị na-eme egwuregwu nwere mmetụta; Otú ọ dị, a ga-edobe nke a maka ndị na-eme egwuregwu dị elu nke nwere akụkọ ihe mere eme nke mgbaàmà siri ike n'okpuru nlekọta dị mma. Ụfọdụ ndị na-eme egwuregwu nwere ike irite uru site na iji mgbasawanye. Usoro ọgwụgwọ IV na-emekarị abụghị nhọrọ kacha mma. Ụdị Outlook Dabere na ụdị, a na-ekewa ahịa ahụ n'ime catheters intravenous, nfuli infusion, agịga hypodermic, ọdụ ụgbọ mmiri a na-akụnye, na ndị ọzọ. Na 2021, akụkụ catheter intravenous ga-enweta oke ego na-enweta na ya. ọgwụgwọ intravenous (IV) na venous access market.Nke a bụ n'ihi mmụba nke IV catheters n'oge usoro ịwa ahụ maka ọgwụgwọ IV na n'oge a na-ebufe ọbara, ọgwụ, na ihe ndị ọzọ na-edozi ahụ n'akụkụ dị iche iche nke ahụ. A na-etinye ya n'ime oghere ahụ ma ọ bụ lumen. Otu catheter intravenous bụ catheter intravenous nke a na-eji na-ebuga ọgwụ, mmiri mmiri, ma ọ bụ ọgwụgwọ ndị ọzọ ozugbo n'ime ọbara. A na-ebutekarị ha n'ime akwara na ogwe aka, ọ bụ ezie na a pụkwara itinye ha n'ime eriri afọ. olu, obi, ma ọ bụ ukwu.Catheters intravenous na-abịa n'ụdị nha na ụdị dị iche iche, dabere na ebumnuche ha. Mpaghara Outlook Dabere na mpaghara, a na-ekewa ahịa ahụ n'ime North America, Europe, Asia Pacific & Latin America, Middle East & Africa. .Na 2021, North America bụ mpaghara na-ebute ụzọ na ọgwụgwọ intravenous (IV) na venous ohere ahịa site n'iwere òkè ahịa ego kachasị elu. Enwere ike ịsị na uto nke ahịa mpaghara na-abawanye na ọnụ ọgụgụ nke ndị ọrịa, na-arị elu nke omume. ihe mberede okporo ụzọ, ọganihu dị elu na ọnọdụ trauma, na ịba ụba nke ntinye ego nke gọọmenti etiti n'ịzụlite ụlọ ọrụ ahụike ka mma na ọrụ R & D. Akụkọ nyocha ahịa na-ekpuchi nyocha nke ndị isi na-ahụ maka ahịa ahụ. Ụlọ ọrụ ndị isi na-akọwapụta na akụkọ ahụ gụnyere B. Braun Melsungen AG, Medtronic PLC, Terumo Corporation, Fresenius SE & Co. KGaA, Cardinal Health, Inc., Pfizer, Inc., Teleflex, Inc., Baxter International, Inc., Smiths Group PLC na AngioDynamics, Inc. Deploy Strategies in the Intravenous (IV) ) Therapy and intravenous Access Market March 2022: Fresenius Kabi bịanyere aka n'akwụkwọ nkwekọrịta iji nweta Fresenius Kabi, ụlọ ọrụ ahụike zuru ụwa ọnụ. Nnweta, nke e mere iji jikọta usoro infusion nke Ivenix n'ime Fresenius Kabi's portfolio nke intravenous infusion na infusion ọgwụgwọ ngwaahịa, ga-eweta a. Ngwakọta ngwaahịa sara mbara na ụlọ ọgwụ US.December 2021: Baxter na-emepụta mmekorita ya na onye na-ahụ maka teknụzụ ahụike US Hillrom.Site na mmekorita a, ụlọ ọrụ abụọ ahụ bu n'obi ikpokọta azụmaahịa isi teknụzụ ọgwụ ahụike abụọ iji nweta otu ọhụụ nke ịgbanwe nlekọta ahụike zuru ụwa ọnụ yana melite nlekọta ndị ọrịa. Mee 2021: Smiths Medical ụdị mmekorita ya na ụlọ ọrụ teknụzụ ahụike Ivenix.Site na mmekorita a, ụlọ ọrụ abụọ ahụ bu n'obi ịnye ọtụtụ ngwọta nchịkwa infusion. Ọzọkwa, Smiths Medical ga-enye ntinye ego dị mkpa na mmekorita ogologo oge e mere iji gbanwee njikwa ngwakọta. ma kwalite ahụike onye ọrịa, ebe ọ na-egbo mkpa ndị na-ahụ maka ahụike.April 2021: B. Braun Medical weputara mmemme ọhụrụ, Uru Peripheral, iji kwalite ahụmịhe ndị ọrịa na ọgwụgwọ intravenous n'akụkụ. ngwá ọrụ dị mma iji mee ka ndị nọọsụ nwee ike nweta ihe ịga nke ọma nke mbụ ma nyere aka zere mgbagwoju anya metụtara ọgwụgwọ IV. Julaị 2019: Baxter na-enweta nkwado US Food and Drug Administration (FDA) maka Myxredlin. Nkwenye na-enye ohere maka insulin ozugbo maka intravenous intravenous n'ụlọ ọgwụ. na ntọala nlekọta ndị ọzọ kpụ ọkụ n'ọnụ ma nwee ogologo ndụ dị ukwuu nke ụbọchị 30 ma ọ bụ ọnwa 24 na ụlọ okpomọkụ ma ọ bụrụ na etinyere ya na ngwa nju oyi na nkwakọ ngwaahịa mbụ iji hụ na nchebe pụọ na ìhè. • Ngwaahịa ọbara • Ngwọta nri na ihe ndozi • Ụgbọ mmiri na-ekesa site n'ụdị • Catheters intravenous • Nfuli ntụtụ • Needles hypodermic • ọdụ ụgbọ mmiri a na-akụnye • Ndị ọzọ sitere na Geography • North America o USo Canadao Mexico Rest of North America • Europe Germany o UKo France Russia Spain Italy o Europe fọdụrụ • Asia Pacific China o Japan India Korea Singapore Malaysia o fọdụrụ Asia Pacific • LAMEAo Brazil Argentina UAE Saudi Arabia South Africa Nigeria LAMEA Rest Company Profaịlụ • B. Braun Melsungen AG • Medtronic PLC• Terumo Corporation• Fresenius SE & Co. KGaA• Kadinal Health, Inc.• Pfizer, Inc.• Teleflex, Inc.• Baxter International, Inc.• Smiths Group PLC• AngioDynamics, Inc. Onyinye Pụrụ iche • Mkpuchi Na-agwụ agwụ • Tebụl ahịa & Data Kachasị ukwuu • Ụdị ndenye aha dabeere na dị. • Ọnụ ahịa kacha mma na-ekwe nkwa • Nchoputa nleba anya mgbe emechara ya site na nhazi 10% Gụọ akụkọ zuru ezu n'efu: https://www .reportlinker.com/p06283441/?utm_source=GNWAbout ReportlinkerReportLinker bụ ihe nrite na-emeri ahịa nyocha.Reportlinker chọtara. ma hazie data ụlọ ọrụ kachasị ọhụrụ ka ị nwee ike nweta nyocha ahịa niile ịchọrọ ozugbo n'otu ebe.